Liver Cancer Institute, Fudan University, Shanghai, China.
Oncology. 2011;81 Suppl 1:116-22. doi: 10.1159/000333273. Epub 2011 Dec 22.
Liver transplantation (LT) is a viable therapeutic option for hepatocellular carcinoma (HCC). Many criteria, such as the Milan criteria and the University of California at San Francisco (UCSF) criteria, have been established to select a subset of HCC patients who stand to benefit from LT. However, they are still insufficient for predicting HCC patients at high risk for recurrence and selecting those at low risk. Many molecules which are probable candidates for recognizing HCC patients at high or low risk for recurrence give a wider perspective to consider for LT indication. Besides working as biomarkers, most of them are also functionally involved in some important pathways which contribute to HCC metastasis. The complex network constituted by them shows a multichannel, multistep HCC metastatic process which indicates difficulty in tumor therapy. Given the efficacy of some molecular targeted drugs in the treatment of HCC or prevention of tumor recurrence after LT, the emerging molecular targeted therapy is also discussed in this review.
肝移植（LT）是治疗肝细胞癌（HCC）的可行方法。已经建立了许多标准，例如米兰标准和加利福尼亚大学旧金山分校（UCSF）标准，以选择一组可能从 LT 中受益的 HCC 患者。然而，这些标准仍然不足以预测 HCC 患者的高复发风险，并选择低复发风险的患者。许多可能被认为是识别 HCC 患者高或低复发风险的候选分子为 LT 适应证提供了更广泛的视角。除了作为生物标志物外，其中大多数还在某些重要途径中发挥功能，这些途径有助于 HCC 的转移。由它们构成的复杂网络显示出多通道、多步骤 HCC 转移过程，这表明肿瘤治疗具有难度。鉴于一些分子靶向药物在 HCC 治疗或 LT 后预防肿瘤复发方面的疗效，本综述还讨论了新兴的分子靶向治疗。
